Prostate specific membrane antigen (PSMA) and Prostate Cancer Staging: is our current conventional staging obsolete?
- PMID: 33861056
- PMCID: PMC8486444
- DOI: 10.1590/S1677-5538.IBJU.2020.0997
Prostate specific membrane antigen (PSMA) and Prostate Cancer Staging: is our current conventional staging obsolete?
Conflict of interest statement
None declared.
References
-
- 1. Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021;79:243-62. - PubMed
-
- 3. Briganti A, Blute ML, Eastham JH, Graefen M, Heidenreich A, Karnes JR, et al. Pelvic lymph node dissection in prostate cancer. Eur Urol. 2009; 55:1251-65. - PubMed
-
- 4. Eiber M, Herrmann K, Fendler WP, Maurer T. 68Ga-labeled Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Imaging: The New Kid on the Block-Early or Too Early to Draw Conclusions? Eur Urol. 2016; 70:938-940. - PubMed
-
- 5. Hicks RJ, Murphy DG, Williams SG. Seduction by Sensitivity: Reality, Illusion, or Delusion? The Challenge of Assessing Outcomes after PSMA Imaging Selection of Patients for Treatment. J Nucl Med. 2017; 58:1969-71. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous